Factors influencing false-positive results of rifampicin resistance detected by Xpert MTB/RIF: A retrospective study in Zhejiang, China

被引:0
|
作者
Wu, Guihua [1 ]
Wang, Jing [1 ]
Xu, Xiaoqun [1 ]
Wei, Hui [1 ]
Cai, Long [1 ]
Liu, Libin [1 ]
机构
[1] Hangzhou Red Cross Hosp, Ctr Lab Med, Hangzhou, Zhejiang, Peoples R China
关键词
Rifampicin resistance; Probe mutation; Probe delay; Influencing factors; MYCOBACTERIUM-TUBERCULOSIS; MUTATION; ASSAY;
D O I
10.1016/j.heliyon.2024.e31680
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective: This study aimed to explore the factors influencing false-positive results for rifampicin resistance (RIF-R) detected using Xpert MTB/RIF (Xpert). Methods: This retrospective analysis included the clinical data of patients from September 2019 to February 2023. The chi-square and rank sum tests were used to compare differences in patient characteristics between the true-positive and false-positive groups. Logistic regression was used to analyze the factors influencing false positives in the detection of RIF-R by Xpert. Results: A total of 384 patients were included. Logistic regression analysis revealed that, with mutation of probe E as the reference, mutations on probe A or C (OR = 72.68, P < 0.001), probe D (OR = 6.44, P < 0.001), and multiple probes (OR = 5.94, P = 0.002) were associated with false-positive results in Xpert detection of RIF-R. Taking probe delay Delta Ct <4 as the reference, Delta Ct (4-5.9) (OR = 13.54, P < 0.001), Delta Ct (6-7.9) (OR = 48.08, P < 0.001) probe delays were associated with false positives in Xpert detection of RIF-R. When very low quantification is accompanied by a probe delay, the probability of false-positive RIF-R detection can reach 80 %. Conclusions: Clinicians should consider factors such as probe mutation type, probe delay, and very low quantification accompanied by probe delay when interpreting Xpert results, which can reduce the misdiagnosis of tuberculosis drug resistance.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] An evaluation of false-positive rifampicin resistance on the Xpert MTB/RIF
    Cayci, Yeliz Tanriverdi
    Bilgin, Kemal
    Coban, Ahmet Yilmaz
    Birinci, Asuman
    Durupinar, Belma
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2017, 112 (11): : 756 - 759
  • [2] Management of false-positive rifampicin resistant Xpert MTB/RIF
    Beylis, Natalie
    Ghebrekristos, Yonas
    Nicol, Mark
    LANCET MICROBE, 2020, 1 (06): : E238 - E238
  • [3] False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications
    Van Rie, A.
    Mellet, K.
    John, M-A.
    Scott, L.
    Page-Shipp, L.
    Dansey, H.
    Victor, T.
    Warren, R.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2012, 16 (02) : 206 - 208
  • [4] An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis
    Williamson, Deborah A.
    Basu, Indira
    Bower, James
    Freeman, Joshua T.
    Henderson, Gillian
    Roberts, Sally A.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2012, 74 (02) : 207 - 209
  • [5] False-positive rifampicin resistance on Xpert® MTB/RIF caused by a silent mutation in the rpoB gene
    Mathys, V.
    van de Vyvere, M.
    de Droogh, E.
    Soetaert, K.
    Groenen, G.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2014, 18 (10) : 1255 - 1257
  • [6] Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda
    Ngabonziza, Jean Claude Semuto
    Decroo, Tom
    Migambi, Patrick
    Habimana, Yves Mucyo
    Van Deun, Armand
    Meehan, Conor J.
    Torrea, Gabriela
    Massou, Faridath
    de Rijk, Willem Bram
    Ushizimpumu, Bertin
    Niyigena, Esdras Belamo
    Ivan, Emil
    Semahore, Jules Mugabo
    Mazarati, Jean Baptiste
    Merle, Corinne Simone
    Supply, Philip
    Affolabi, Dissou
    Rigouts, Leen
    de Jong, Bouke Catherine
    LANCET MICROBE, 2020, 1 (02): : E74 - E83
  • [7] False-positive Xpert® MTB/RIF assays and previous treatment
    Boyles, Tom H.
    Hughes, Jennifer
    Cox, Vivian
    Burton, Rosie
    Meintjes, Graeme
    Mendelson, Marc
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2015, 19 (04) : 495 - 496
  • [8] Retrospective Analysis of False-Positive and Disputed Rifampin Resistance Xpert MTB/RIF Assay Results in Clinical Samples from a Referral Hospital in Hunan, China
    Hu, Peilei
    Zhang, Hongtai
    Fleming, Joy
    Zhu, Guofeng
    Zhang, Shuai
    Wang, Yaguo
    Liu, Fengping
    Yi, Songlin
    Chen, Zhongnan
    Chen, Zhenhua
    Liu, Binbin
    Gong, Daofang
    Wan, Li
    Wang, Xingyun
    Tan, Yunhong
    Bai, Liqiong
    Bi, Lijun
    JOURNAL OF CLINICAL MICROBIOLOGY, 2019, 57 (04)
  • [9] In reply to 'False-positive Xpert® MTB/RIF assays in previously treated patients'
    Steingart, Karen R.
    Schiller, Ian
    Dendukuri, Nandini
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2015, 19 (03) : 366 - 367
  • [10] False-positive Xpert® MTB/RIF assays in previously treated patients: need for caution in interpreting results
    Boyles, T. H.
    Hughes, J.
    Cox, V.
    Burton, R.
    Meintjes, G.
    Mendelson, M.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2014, 18 (07) : 876 - 878